April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Gilteritinib Submitted for FDA Approval in FLT3+ AML
April 26th 2018Based on data from the ongoing phase III ADMIRAL study, Astellas Pharma, the manufacturer of gilteritinib, has announced the submission of a new drug application to the FDA seeking approval for the FLT3 inhibitor as a treatment for adult patients with <em>FLT3</em> mutation–positive relapsed or refractory acute myeloid leukemia.
Read More
Voxtalisib Shows Promising Activity in Follicular Lymphoma
April 24th 2018Voxtalisib (XL765) monotherapy induced objective responses in 41.3% of patients with follicular lymphoma, but displayed minimal efficacy in patients with other lymphomas, according to results from a phase II trial of patients with relapsed or refractory lymphoma or chronic lymphocytic leukemia that were recently published in the Lancet Haematology.
Read More
Targeted Oncology To Launch Virtual Tumor Board
April 23rd 2018<em>Targeted Oncology</em>™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field.
Read More
Venetoclax Shows Promise as Salvage Therapy in CLL
April 18th 2018Venetoclax induced a response in two-thirds of patients with relapsed/refractory chronic lymphocytic leukemia who had progressed after receiving prior therapy with idelalisib, according to findings of a phase II study recently published in <em>Blood</em>.
Read More
BLU-667 Demonstrates Broad Activity in RET+ Advanced Solid Tumors
April 16th 2018According to the results from a phase I study, BLU-667, a next-generation tyrosine kinase inhibitor, was well-tolerated and demonstrated clinical benefit in patients with advanced, <em>RET</em>-altered solid tumors who had progressed on previous therapies. These findings were presented April 14 to 18 at the ASCR Annual Meeting 2018 in Chicago, Illinois.
Read More
Selecting Patients for Treatment With Ibrutinib in CLL
April 14th 2018Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib
Watch
Triplet Combination of Ibrutinib, Venetoclax, and Obinutuzumab Effective as Initial CLL Treatment
April 11th 2018According to preliminary results of a phase II trial, the combination of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) is a safe initial therapy for treatment-naïve patients with chronic lymphocytic leukemia (CLL).
Read More
Expert Discusses Novel Treatment Options for Relapsed/Refractory CLL
April 10th 2018According to Neil E. Kay, MD, novel agents, such as ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib (Zydelig), and acalabrutinib (Calquence), are revolutionizing treatment for patients with chronic lymphocytic leukemia. However, the best way to sequence these agents to maximize the benefit to patients is still unclear.
Read More
Duvelisib Granted Priority Review by FDA for CLL and Follicular Lymphoma
April 9th 2018A new drug application seeking a full approval for duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma has been granted a priority review by the FDA.
Read More
Expert Highlights Potential of Targeted Therapies in Combinations for CLL
April 5th 2018The treatment paradigm of chronic lymphocytic leukemia continues to advance, with many ongoing clinical trials investigating combinations seeking to build upon the success seen with Bruton’s tyrosine kinase inhibitors. Such potential combination therapies for CLL include venetoclax (Venclexta) with either ibrutinib (Imbruvica) or acalabrutinib (Calquence).
Read More
Moxetumomab Pasudotox Granted FDA's Priority Review Designation for Hairy Cell Leukemia
April 4th 2018Moxetumomab pasudotox has been granted a priority review by the FDA for the treatment of adult patients with hairy cell leukemia (HCL) who have received at least 2 prior lines of therapy, according to AstraZeneca (MedImmune), the developer of the anti-CD22 recombinant immunotoxin.
Read More
MURANO Trial Results Demonstrate PFS Benefit with Venetoclax/Rituximab
March 24th 2018According to findings from the phase III MURANO trial recently published in the<em> New England Journal of Medicine, </em>the venetoclax (Venclexta) plus rituximab (Rituxan) regimen lowered the risk of disease progression or death by 83% in comparison with bendamustine (Treanda) plus rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic leukemia<em>.</em>
Read More